Flu Season Still Gripping the Nation: Child Deaths Rise, But Signs of Slowing

For the second consecutive week, the United States is reporting 11 influenza-related deaths in children, bringing the total pediatric deaths for the season to 101. While flu activity remains elevated nationwide, recent data from the Centers for Disease Control and Prevention (CDC) suggests a potential slowing of the surge, though the season is still classified as “high severity” for children.

Flu Indicators Show Early Signs of Decline

The CDC’s latest FluView report, covering the week ending March 7, indicates a slight decrease in several key indicators. Test positivity for flu decreased to 15.3% from 15.8% the previous week. Healthcare visits related to respiratory illness also saw a minor dip, falling from 3.9% to 3.7% of all visits. Hospitalizations for flu totaled 9,130, down from 10,763 the week prior. The percentage of deaths attributed to influenza also declined, moving from 0.7% to 0.5%.

Despite these declines, the cumulative flu hospitalization rate remains the third highest since the 2010-11 flu season, with children experiencing the second-highest cumulative hospitalization rate for their age group during that same period.

Dominant Strain and Vaccination Rates

Influenza A viruses continue to be the predominant strain circulating, but are showing signs of decline. Of the influenza A viruses genetically tested, 92.5% were identified as the A(H3N2) subclade K. A concerning statistic remains the vaccination status of those who have died; approximately 85% of the 101 children who have succumbed to the flu this season were unvaccinated.

Did you know? The CDC estimates that at least 27 million Americans have been infected with the flu this season, leading to 350,000 hospitalizations and 22,000 deaths.

RSV Season May Extend into Spring

Alongside the flu, respiratory syncytial virus (RSV) continues to circulate. The CDC predicts that the RSV season may extend into April in many areas of the United States, as activity started later than usual this year. Wastewater surveillance data from WastewaterSCAN indicates high levels of influenza A and B, RSV and human metapneumovirus, with moderate levels of SARS-CoV-2.

Protecting Vulnerable Populations

Children younger than 5 years old—especially those younger than 2—and children of any age with chronic health conditions are at higher risk of developing serious flu-related complications. Vaccination remains the most effective way to protect against the flu and its potential consequences. The CDC recommends annual flu vaccination for everyone 6 months, and older.

Pro Tip: Beyond vaccination, practicing good hygiene – frequent handwashing, covering coughs and sneezes – can significantly reduce the spread of respiratory viruses.

FAQ About the Current Flu Season

Q: Is it too late to get a flu shot?
A: No, it’s not too late. While the vaccine is most effective when received early in the season, it can still provide protection even later on.

Q: What are the symptoms of the flu?
A: Common symptoms include fever, cough, sore throat, muscle aches, fatigue, and headache.

Q: How can I protect my family from the flu?
A: Get vaccinated, practice good hygiene, and stay home if you are sick.

Q: What should I do if I think I have the flu?
A: Contact your healthcare provider for advice and potential treatment options.

Want to learn more about protecting yourself and your family from respiratory illnesses? Visit the CDC’s influenza page for the latest information and resources.

The Hidden Cost of Weight Loss Drugs: Nutrient Deficiencies and the Future of GLP-1 Therapy

The rise of medications like semaglutide and tirzepatide has revolutionized weight loss, but a growing body of evidence suggests a potential downside: increased risk of nutrient deficiencies. While these drugs effectively curb appetite and promote weight reduction, they can also inadvertently limit the absorption of essential vitamins and minerals. This isn’t a future concern – it’s happening now, and healthcare professionals are beginning to adapt their approach.

How GLP-1s Impact Nutrient Absorption

Semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GLP-1/GIP agonist, operate by mimicking gut hormones that regulate appetite and food intake. This leads to reduced food consumption, which, if not carefully managed, can translate to lower intake of vital nutrients. Gastrointestinal side effects, such as nausea, vomiting, and diarrhea, common during the initial stages of treatment, can further exacerbate these deficiencies.

Recent data highlights the extent of the problem. A retrospective analysis revealed that 12.7% of patients experienced diagnosed nutrient deficiencies after six months on a GLP-1 receptor agonist, rising to 22.4% after 12 months. Vitamin D deficiency was the most frequently observed, but deficiencies in other key nutrients are also emerging.

Beyond Vitamin D: A Wider Spectrum of Deficiencies

Studies analyzing dietary intake among GLP-1 users demonstrate consistently lower consumption of essential nutrients. Specifically, intakes of fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E are often below recommended levels. Even when protein intake appears adequate as a percentage of calories, the absolute amount consumed (grams per day or per kilogram of body weight) can be insufficient, particularly with significant calorie restriction.

Did you know? Individuals already prone to nutrient deficiencies – such as older adults, those with limited diets, or individuals with pre-existing malabsorption issues – may be at even higher risk while on GLP-1 therapy.

The Importance of Protein and Bone Health

Maintaining muscle mass is crucial during weight loss, and adequate protein intake is paramount. The recommended daily protein intake is 0.8 g/kg for adults (19-65 years) and 1.0 g/kg for those over 65. For individuals on GLP-1s, prioritizing protein-rich foods with each meal – such as dairy products, eggs, fish, legumes, or lean meats – is essential. Protein shakes or high-protein snacks can also be beneficial.

Bone health is another critical consideration. Rapid weight loss can lead to decreased bone mineral density, particularly in postmenopausal women and older adults. Combining GLP-1 therapy with strength training and ensuring sufficient calcium and vitamin D intake can help mitigate this risk. A randomized study demonstrated that combining GLP-1 receptor agonists with structured exercise provided the best preservation of bone health compared to GLP-1 therapy alone.

Hair Loss: A Visible Sign of Underlying Deficiencies?

Increasingly, patients are reporting hair loss as a side effect of rapid weight loss with GLP-1s. This is often attributed to telogen effluvium, a condition triggered by stressors like rapid weight change and nutrient deficiencies (iron, zinc, vitamin D). While a direct causal link hasn’t been definitively established, the association is strong enough to warrant investigation and nutritional support.

Future Trends: Personalized Nutrition and Proactive Monitoring

The future of GLP-1 therapy will likely involve a more integrated approach that prioritizes nutritional support and proactive monitoring. Here’s what we can expect:

• Personalized Nutrition Plans: Tailored dietary recommendations based on individual needs, medical history, and potential risk factors.
• Routine Nutrient Screening: Regular blood tests to assess vitamin and mineral levels, particularly in high-risk patients.
• Supplementation Strategies: Targeted supplementation to address identified deficiencies, guided by healthcare professionals.
• Enhanced Patient Education: Comprehensive education on the importance of nutrient-dense foods and strategies for maximizing nutrient absorption.
• Integration with Telehealth: Remote monitoring and virtual consultations with registered dietitians to provide ongoing support.

Pro Tip: Don’t wait for symptoms to appear. Proactively discuss potential nutrient deficiencies with your healthcare provider before starting GLP-1 therapy.

The Role of the Pharmacy in Nutritional Support

Pharmacists are uniquely positioned to play a crucial role in supporting patients on GLP-1 therapy. They can provide counseling on nutrient-rich food choices, recommend appropriate supplements, and identify potential drug-nutrient interactions. Offering resources on protein-rich snacks, calcium-rich foods, and strategies for managing gastrointestinal side effects can significantly improve patient outcomes.

FAQ

Q: What are the most common nutrient deficiencies associated with GLP-1s?
A: Vitamin D, iron, calcium, vitamin B12, and magnesium are frequently observed.

Q: Should everyone on a GLP-1 take a multivitamin?
A: Not necessarily. A personalized approach based on individual needs and risk factors is best. Blood tests can help identify specific deficiencies.

Q: Can I prevent nutrient deficiencies while on a GLP-1?
A: Yes, by prioritizing nutrient-dense foods, staying hydrated, and working closely with your healthcare team.

Q: Is hair loss a common side effect of GLP-1s?
A: It’s increasingly reported and may be linked to nutrient deficiencies and the stress of rapid weight loss.

This evolving understanding of the interplay between GLP-1 therapy and nutrient status underscores the need for a holistic approach to weight management. Addressing potential deficiencies proactively will not only optimize treatment outcomes but also safeguard the long-term health and well-being of patients.

Want to learn more about optimizing your health while on GLP-1 therapy? Explore our articles on protein intake for weight loss and the importance of vitamin D.